SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.
File(s)s41467-021-21237-w.pdf (667.52 KB)
Published version
Author(s)
Type
Journal Article
Abstract
England has experienced a large outbreak of SARS-CoV-2, disproportionately affecting people from disadvantaged and ethnic minority communities. It is unclear how much of this excess is due to differences in exposure associated with structural inequalities. Here we report from the REal-time Assessment of Community Transmission-2 (REACT-2) national study of over 100,000 people. After adjusting for test characteristics and re-weighting to the population, overall antibody prevalence is 6.0% (95% CI: 5.8-6.1). An estimated 3.4 million people had developed antibodies to SARS-CoV-2 by mid-July 2020. Prevalence is two- to three-fold higher among health and care workers compared with non-essential workers, and in people of Black or South Asian than white ethnicity, while age- and sex-specific infection fatality ratios are similar across ethnicities. Our results indicate that higher hospitalisation and mortality from COVID-19 in minority ethnic groups may reflect higher rates of infection rather than differential experience of disease or care.
Date Issued
2021-02-10
Date Acceptance
2021-01-06
Citation
Nature Communications, 2021, 12 (905), pp.1-8
ISSN
2041-1723
Publisher
Nature Research
Start Page
1
End Page
8
Journal / Book Title
Nature Communications
Volume
12
Issue
905
Copyright Statement
© The Author(s) 2021. This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
License URL
Sponsor
Department of Health
National Institute of Health Research
National Institute for Health Research
UK Research and Innovation
Imperial College Healthcare NHS Trust: Research Capability Funding (RCF)
Medical Research Council (MRC)
Identifier
https://www.nature.com/articles/s41467-021-21237-w
Grant Number
n/a
RP-2016-07-012
9815274 MC_PC_19025
RDF04
MR/R015600/1
Publication Status
Published
Article Number
NCOMMS-20-37490B
Date Publish Online
2021-02-10